Chemical formula: C₆₃H₉₁CoN₁₃O₁₄P Molecular mass: 1,344.382 g/mol PubChem compound: 71306319
Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy. Clinical studies have been done on pregnant women and no harmful effects have been reported.
Labelled mecobalamin 57Co-CH3-B12 10μg/kg was administered intravenously to pregnant rats. Peak radioactivity concentrations in placenta and fetus were reached 30 minutes and 24 hours after the injection, respectively.
It has been shown that mecobalamin is excreted in the milk of lactating rats.
Labeled mecobalamin 57Co-CH3-B12 10μg/kg was administered intravenously to rats. Radioactivity concentration in breast milk reached its peak (42.9ng eq/mL) 6 hours after the administration, and gradually decreased thereafter.
Based on the pharmacodynamic properties and adverse events profile, it is unlikely that mecobalamin would cause an impairment of driving performance or compromise the ability to use machinery.
No psychoneurological disorders have been reported such as sleepiness, confusion and movement disorders.
Adverse reactions were reported in 146 of 15,180 patients (0.96%). (At the end of the investigation for incidence of adverse reactions).
| 5% > ≥0.1% | <0.1% | |
|---|---|---|
| Gastrointestinal | Anorexia, nausea/vomiting and diarrhea | |
| Hypersensitivitynote | Rash |
note: In the event of such symptoms, treatment with Methycobal
Tablets should be discontinued.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
